CSIMarket


National Research Corporation  (NRC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare


 

National Research Corporation

NRC's Financial Statements and Analysis



National Research Corporation reported in the forth quarter of 2023 net earnings per share of $0.36 an increase by 34.48 % year on year from $0.27 and an improvement of 13.28 % from $0.32 realized in III. Quarter (Sep 30 2023).


forth quarter of 2023
Earnings Per Share Revenues
$ 0.36 $  38 Mill
$+0.09     +34.48 % Unch.     -0.37 %



National Research's Revenue fell by -0.37 % in forth quarter of 2023 (Dec 31 2023) year on year, to $38 million and advanced by 0.15 % sequentially.


National Research is

More on NRC's Income Statement



National Research's net income of $8.858 million in the forth quarter of 2023 increased by 33.38 % from net earnings of $6.641 million achieved in IV. Quarter a year ago.

Sequentially net earnings grew by 12.47 % from net income of $7.876 million realized in previous quarter.

More on NRC's Growth

National Research Inventories
NRC's Cash flow In the forth quarter of 2023 company's net cash flow was $3 million, capital expenditures fell by -1.96691.76%, to $-4 millions compare to same quarter a year ago

More on NRC's Cash flow Statement


National Research Corporation payed out dividend of $1.47 per share in last 52 weeks representing 117.60 % of net earning per share in trailing twelve-month period.

During the same period National Research Corporation earned $ 1.54 cash per share, on a free-cash flow basis 123.06 % of net earning per share.

Book value fell by -15.69 % sequentially to $1.98 per share.
Tangible Book value fell to $ -0.57 per share from $ -0.21.

Company issued 0.08 million shares or 0.33 % in Dec 31 2023.
Interest Coverage Ratio was 47.36. Debt Coverage Ratio was 1.69.

More on NRC's Dividends

 Market Capitalization (Millions) 984
 Shares Outstanding (Millions) 25
 Total Debt (Millions $) 37
 Revenue (TTM) (Millions $) 149
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) -16
 Dividend TTM ($) 1.47 $
 Dividend Yield TTM (%) 1.21 %
 Employees (TTM) $ -




National Research Corporation payed out dividend of $1.47 per share in the last 52 weeks representing 117.60 % of net earning per share in trailing twelve-month period.

During the same period National Research Corporation had $ 1.54 cash flow per share, on a free-cash flow basis 123.06 % of net earning per share.

Book value fell by -15.69 % sequentially to $1.98 per share.
Tangible Book value fell to $ -0.57 per share from $ -0.21.

Company issued 0.08 million shares or 0.33 % in Dec 31 2023.
Interest Coverage Ratio was 47.36. Debt Coverage Ratio was 1.69.

More on NRC's Balance Sheets

 Market Capitalization (Millions) 984
 Shares Outstanding (Millions) 25
 Total Debt (Millions $) 37
 Revenue (TTM) (Millions $) 149
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) -16
 Dividend TTM ($) 1.47 $
 Dividend Yield TTM (%) 1.21 %
 Employees (TTM) $ -
   


  News about National Research Corporation Earnings

Breaking Down the Financial Success of NRC Health: A Look at Revenue Consolidation and Earnings Growth in Q4 2023



National Research Corporation (NRC Health) recently released its financial results for the fourth quarter and full calendar year of 2023. Despite a decrease in revenue, the company managed to increase its earnings per share (EPS) and net profits. The CEO, Michael Hays, expressed satisfaction with the company's growth in new sales and operating margin. Additionally, the company achieved a new high in its dividend payout ratio during the third quarter of 2023.
Financial Facts:
1. EPS Growth: NRC Health experienced a 34.48% increase in profit per share, reaching $0.36 per share in the most recent fiscal period. This compares to $0.32 per share in the previous reporting period.
2. Revenue D...

NRC experiences significant revenue growth in Q3 2023, setting new industry standards

National Research Corporation, dba NRC Health, recently announced its financial results for the third quarter of 2023. Despite a slight elevation in revenue of 0.674%, the company experienced a decline in income of -3.03% compared to the same reporting period a year earlier. However, it is important to note that the company's revenue stood at an impressive $37.95 million, accompanied by an EPS of $0.32.
In comparison to the Medical Laboratories sector, NRC's revenue growth fell short by 3.35% during the same period. This may not be ideal, but it is worth mentioning that the company managed to grow its EPS by 10.34% from the previous reporting period. Additionally, the revenue also witnessed a healthy ris...

National Research Corporation Surprises with an Unexpected 3.03% Revenue Dip between April and June 2023



National Research Corporation recently released its financial results for the April to June 30, 202...

National Research Corporation Faces Profitability Plunge with -17.65% EPS Deterioration in Q1 2023

National Research Corporation (NRC) has been experiencing a significant decline in profitability in the first quarter of the year 2023, with the income falling by -17.65% to per share $0.28, and the rev...


Date modified: 2024-02-28T15:30:04+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com